candesartan has been researched along with Ovarian Neoplasms in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suganuma, T | 1 |
| Ino, K | 1 |
| Shibata, K | 1 |
| Kajiyama, H | 1 |
| Nagasaka, T | 1 |
| Mizutani, S | 1 |
| Kikkawa, F | 1 |
1 other study available for candesartan and Ovarian Neoplasms
| Article | Year |
|---|---|
Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Topics: Adenocarcinoma; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antigens, CD34; Be | 2005 |